ADMA Biologics Revenue and Competitors
Estimated Revenue & Valuation
- ADMA Biologics's estimated annual revenue is currently $82.2M per year.
- ADMA Biologics received $41.9M in venture funding in November 2017.
- ADMA Biologics's estimated revenue per employee is $217,000
- ADMA Biologics's total funding is $547.4M.
Employee Data
- ADMA Biologics has 379 Employees.
- ADMA Biologics grew their employee count by 6% last year.
ADMA Biologics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is ADMA Biologics?
ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906. For more information, please visit the company's website at www.admabiologics.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$547.4M
Total Funding
379
Number of Employees
$82.2M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ADMA Biologics News
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the...
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-...
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-...
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Loss ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously anno ...
Other Companies in Ramsey
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $86.4M | 461 | 0% | N/A |
#2 | $150.7M | 492 | 3% | N/A |
#3 | N/A | 562 | N/A | N/A |
#4 | $126.7M | 563 | N/A | N/A |
#5 | $243.4M | 590 | -2% | N/A |
ADMA Biologics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-12-16 | $5.0M | Undisclosed | Hercules Technology Growth Capital, Inc | Article |
| 2015-03-19 | $10.3M | Undisclosed | Raymond James | Article |
| 2015-06-23 | $21.0M | Undisclosed | Oxford Finance | Article |
| 2017-11-10 | $41.9M | Undisclosed | Raymond James & Associates, Inc | Article |